Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 1.00 |
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP13 | P45452 | 19/20 | 1.00 |
| ▸ | MMP9 | P14780 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 0.84 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.84 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.84 |
| ▸ | MMP7 | P09237 | 1/20 | 0.72 |
| ▸ | MMP8 | P22894 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942486 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP13MMP9MMP2 | |
| Propionamide SCHEMBL7428300 | 0.95 | ADAM17 (0.90) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL7493293 | 0.94 | MMP1 (0.90) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL12272905 | 0.93 | ADAM17 (0.86) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL8051411 | 0.93 | MMP1 (0.86) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL7325140 | 0.92 | MMP1 (0.86) | ADAM17MMP1MMP13MMP9MMP2 | |
| Apratastat SCHEMBL2834310 | 0.92 | MMP1 (1.00) | ADAM17MMP1MMP13MMP9MMP2 | |
| Apratastat SCHEMBL3946334 | 0.92 | MMP1 (1.00) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL7325752 | 0.92 | MMP1 (0.86) | ADAM17MMP1MMP13MMP9MMP2 | |
| SCHEMBL3941871 | 0.92 | MMP1 (0.86) | ADAM17MMP1MMP13MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12520839-B2 | Methods and compositions for cryopreservation of cell therapies | THE GEORGE WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | claimed |
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | claimed |
| EP-4176327-B1 | METHOD FOR EVALUATING THE RELATIVE STATE OF AN AIRCRAFT ENGINE | SAFRAN (FR) | 2024-11-13 | — | — | EP | claimed |
| US-20240156867-A1 | ENGINEERED IMMUNE CELL THERAPEUTICS AND METHODS OF USE | Catamaran Bio, Inc. | 2024-05-16 | — | — | US | claimed |
| US-20240025982-A1 | MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME | UNIV JOHNS HOPKINS (US) | 2024-01-25 | — | — | US | claimed |
| US-11880708-B2 | Method for detecting the disappearance of a task | Vitesco Technologies GmbH (DE) | 2024-01-23 | — | — | US | claimed |
| EP-4176327-A1 | METHOD FOR EVALUATING THE RELATIVE STATE OF AN AIRCRAFT ENGINE | SAFRAN (FR) | 2023-05-10 | — | — | EP | claimed |
| WO-2023276626-A1 | HEAT PUMP CYCLE APPARATUS | 株式会社デンソー | 2023-01-05 | — | — | WO | claimed |
| US-20220394971-A1 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | THE GEORGE WASHINGTON UNIVERSITY | 2022-12-15 | — | — | US | claimed |
| WO-2022260968-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING NATURAL KILLER CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20090137569-A1 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-05-28 | — | — | US | claimed |
| EP-1998779-A2 | USE OF (3S)-N-HYDROXY-4-({4-Ý(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | Galderma Research & Development, S.N.C. (FR) | 2008-12-10 | — | — | EP | claimed |
| WO-2007107663-A2 | USE OF (3S)-N-HYDROXY-4-({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-27 | — | — | WO | claimed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | claimed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | claimed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | claimed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | claimed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP1 130/4885MMP13 114/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP1 130/4885MMP13 114/4885 |
| US-20090137569-A1 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions | HRH4, HRH3, HRH2 | ADAM17 3485/4885MMP1 943/4885MMP13 326/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP1 130/4885MMP13 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.